Swiss drugmakers Roche and Novartis Oncology have told Australia to go fly a kite if it expects a company to market a cancer drug in the country without Pharmaceutical Benefits Scheme coverage. The two companies announced their boycott intentions ahead of a Monday hearing by a panel of Australia's Senate.
ThromboGenics is trying to give the TB-403 cancer drug Roche walked away from in 2012 a new lease of life. The arrangement sees ThromboGenics teaming up with life science research institute VIB to create a new biotech focused on shepherding the drug through clinical development.
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
In the checkpoint receptors race, Bristol-Myers Squibb is out in front with the biggest and fastest effort, a comeback Merck is in hot pursuit and Roche/Genentech and AstraZeneca are following but still in the front of the pack.
Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D.
Roche bought up a Stanford University-founded upstart with a promising approach to tracking the spread of cancer, eyeing a new tool in its expansive oncology R&D efforts.
Prothena has filed the paperwork for a follow-on offering that could net it more than $130 million (€121 million). If successful, the offering will leave the transatlantic biotech sitting pretty on a $400 million stockpile of cash as it plots the next steps in the development of its pipeline of in-house and Roche-partnered assets.
Roche's Avastin has been on the market for more than a decade and boasts a long list of valuable approvals. But Roche is not sitting back the status quo, and continues to submit the drug for new uses. Now, the company racked up yet another OK for Avastin, scoring European approval for the drug in combination with chemotherapy to treat women with advanced cervical cancer months after the company got a similar decision from stateside regulators.
Roche sealed its $1.2 billion deal for Foundation Medicine, forging ahead with cancer R&D as it gains a majority stake in the company.